Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: R03AK06

BroPair Spiromax(salmeterol xinafoate;fluticasone propionate)

Asthma

Marketing Authorisation Holder: Teva B.V.

EMA Authorisation: 26/03/2021

INN: salmeterol;fluticasone propionate

Indication

BroPair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about BroPair Spiromax — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.